GeneDx Holdings (WGS) Receivables - Net (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Receivables - Net data on file, last reported at $76.9 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $76.9 million, up 67.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.9 million (up 67.3% YoY), and the FY2025 annual result was $74.4 million, up 97.64% from the prior year.
• Receivables - Net improved to $76.9 million in Q1 2026 per WGS's latest filing, from $74.4 million in the prior quarter.
• Over five years, Receivables - Net peaked at $76.9 million in Q1 2026 and troughed at $445000.0 in Q4 2023.
• A 5-year average of $37.0 million and a median of $37.6 million in 2022 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net plunged 98.83% in 2023, then soared 8355.96% in 2024.
• A 5-year view of Receivables - Net shows it stood at $708000.0 in 2022, then tumbled by 37.15% to $445000.0 in 2023, then soared by 8355.96% to $37.6 million in 2024, then jumped by 97.64% to $74.4 million in 2025, then rose by 3.44% to $76.9 million in 2026.
• Business Quant data shows WGS's Receivables - Net at $76.9 million in Q1 2026, $74.4 million in Q4 2025, and $60.9 million in Q3 2025.